Based on the Stevanato Group SpA stock forecast from 3 analysts, the average analyst target price for Stevanato Group SpA is USD 23.00 over the next 12 months. Stevanato Group SpA’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Stevanato Group SpA is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, Stevanato Group SpA’s stock price was USD 22.72. Stevanato Group SpA’s stock price has changed by +19.52% over the past week, +21.30% over the past month and -14.30% over the last year.
No recent analyst target price found for Stevanato Group SpA
No recent average analyst rating found for Stevanato Group SpA
Company Overview Stevanato Group SpA
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L. Read Less
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operat...Read More
Frequently Asked Questions About Stevanato Group SpA (STVN) Stock
Based on ratings from 3 analysts Stevanato Group SpA's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 1 buy, sell and 8 hold ratings.
STVN stock's dividend yield is 0.29%.
Our analysis grades STVN stock's dividend yield at F. This means that STVN stock's dividend yield is above 25% of the stocks in the Medical Instruments & Supplies sector in the NYE exchange.
Based on this STVN may be a poor dividend stock for its sector.
Based on targets from 3 analysts, the average taret price for STVN is USD 23.00 over the next 12 months. The maximum analyst target price is USD 28 while the minimum anlayst target price is USD 20.
STVN stock's Price/Earning ratio is 39.18.
Our analysis grades STVN stock's Price / Earning ratio at C-. This means that STVN stock's Price/Earning ratio is above 30% of the stocks in the Medical Instruments & Supplies sector in the NYE exchange.
Based on this STVN may be undervalued for its sector.
The last closing price of STVN's stock was USD 22.72.
The most recent market capitalization for STVN is USD 5.19B.
Based on targets from 3 analysts, the average taret price for STVN is projected at USD 23.00 over the next 12 months.
This means that STVN's stock price may go up by +1.23% over the next 12 months.
We can't find any ETFs which contains Stevanato Group SpA's stock.
As per our most recent records Stevanato Group SpA has 5,635 Employees.
Stevanato Group SpA's registered address is Via Molinella, 17, Piombino Dese, PD, Italy, 35017.
You can get more information about it from Stevanato Group SpA's website at https://www.stevanatogroup.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Stevanato Group SpA (STVN) Stock
Based on ratings from 3 analysts Stevanato Group SpA's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 1 buy, sell and 8 hold ratings.
STVN stock's dividend yield is 0.29%.
Our analysis grades STVN stock's dividend yield at F. This means that STVN stock's dividend yield is above 25% of the stocks in the Medical Instruments & Supplies sector in the NYE exchange.
Based on this STVN may be a poor dividend stock for its sector.
Based on targets from 3 analysts, the average taret price for STVN is USD 23.00 over the next 12 months. The maximum analyst target price is USD 28 while the minimum anlayst target price is USD 20.
STVN stock's Price/Earning ratio is 39.18.
Our analysis grades STVN stock's Price / Earning ratio at C-. This means that STVN stock's Price/Earning ratio is above 30% of the stocks in the Medical Instruments & Supplies sector in the NYE exchange.
Based on this STVN may be undervalued for its sector.
The last closing price of STVN's stock was USD 22.72.
The most recent market capitalization for STVN is USD 5.19B.
Based on targets from 3 analysts, the average taret price for STVN is projected at USD 23.00 over the next 12 months.
This means that STVN's stock price may go up by +1.23% over the next 12 months.
We can't find any ETFs which contains Stevanato Group SpA's stock.
As per our most recent records Stevanato Group SpA has 5,635 Employees.
Stevanato Group SpA's registered address is Via Molinella, 17, Piombino Dese, PD, Italy, 35017.
You can get more information about it from Stevanato Group SpA's website at https://www.stevanatogroup.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for STVN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
